#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS

Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS

Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
#076: Alemtuzumab (Lemtrada, Campath) for highly active Multiple Sclerosis

Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS

Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS

Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#070: Teriflunomide (Aubagio) for relapsing remitting MS

Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#068: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif, …) for CIS, RRMS & SPMS

Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#065: Glatiramer Acetate (Copaxone) for relapsing remitting multiple sclerosis

Glatiramer Acetate belongs to the oldest immunotherapies for relapsing remitting multiple sclerosis and is used for mild or moderate courses.
#062: Dimethyl fumarate (Tecfidera) & Diroximel fumarate (Vumerity) for relapsing remitting MS
Tecfidera and Vumerity, the fumarates for mild or moderate MS kick-off the informative series about immunotherapy for multiple sclerosis.
#015: Living with MS in Belgium. Interview with patient advocate Pieter van Galen

Pieter van Galen is a patient advocate from Belgium who give insight into living with MS in his country and national health care offers.